

Resolutions from the annual general meeting of CombiGene AB, 29 June 2020

Today, on 29 June 2020, CombiGene AB held its annual general meeting ("AGM") in Lund. The AGM elected Filip Funk, lawyer at Fredersen Advokatbyrå, as the chairman of the meeting and keeper of the minutes. The AGM resolved on all matters in accordance with previously published proposed resolutions by the board of directors or the nomination committee. A summary of the most important resolutions adopted follows below.

Dividend

In accordance with the board's proposal, the AGM resolved that no dividend is to be paid for the financial year 2019.

Election of the board of directors, auditor and resolutions on remuneration

Bert Junno, Jan Nilsson, Jonas Ekblom and Per Lundin were elected as new members of the board. Peter Nilsson was re-elected as a board member. Bert Junno was elected as the new chairman of the board of directors. It was resolved that remuneration will amount to SEK 200,000 to the chairman of the board and SEK 125,000 to every other board member who do not receive any salary from the company.

MAZARS SET Revisionsbyrå AB was re-elected as the company's auditor, with Anders O Persson as the principal auditor. The AGM resolved on remuneration according to approved invoices.

Discharge from liability

The AGM resolved to discharge the board of directors and the CEO from liability for the financial year 2019.

Resolution regarding amendment to the Articles of Association

The AGM resolved to amend the Articles of Association according to the table below.

| <i>Previous wording</i> | <i>Resolved wording</i> |
|---|---|
| 1 § Registered name The company's registered name is CombiGene AB. The company is public ("publ"). | 1 § Business name The company's business name is CombiGene AB. The company is public ("publ"). |

| | |
|--|--|
| <p>3 § The object of the company's business The object of the company's business is to develop and commercialize gene therapy for treatment of primarily neurological and psychiatric diseases as well as any other business compatible therewith.</p> | <p>3 § The object of the company's business The object of the company's business is to develop and commercialize gene therapy for treatment of serious diseases that today lack adequate treatment methods as well as any other business compatible therewith.</p> |
| <p>4 § Share capital The share capital shall be not less than SEK 5,000,000 and not more than SEK 20,000,000.</p> | <p>4 § Share capital The share capital shall be not less than SEK 10,000,000 and not more than SEK 40,000,000.</p> |
| <p>5 § Number of shares The number of shares in the company shall be not less than 50,000,000 and not more than 200,000,000.</p> | <p>5 § Number of shares The number of shares in the company shall be not less than 100,000,000 and not more than 400,000,000.</p> |

Authorisation for the board of directors to resolve on new issues of shares, convertibles or warrants

The AGM resolved, in accordance with the proposed resolution in the notice to the AGM, to authorize the board of directors to, on one or more occasions before the next AGM, with or without pre-emption rights for the shareholders, resolve on new issues of shares as well as issues of warrants and/or convertibles.

Lund, 29 June 2020

CombiGene AB

The board of directors

Contacts

Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
jan.nilsson@combigene.com

Arne Ferstad, Chairman of the board
Phone: +447496526142
arne.ferstad@combigene.com

www.combigene.com
CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden
info@combigene.com

About CombiGene

CombiGene's vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies.

CombiGene's business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.

CombiGene's lead project CG01 has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 823282

Attachments

[Resolutions from the annual general meeting of CombiGene AB, 29 June 2020](#)